



診断法の評価

- 海外のBSL4施設保有研究機関との共同研究などで評価
- 世界健康安全保障グループラボラトリーネットワークや国際高度安全実験室ネットワークのEQA参加
- 海外の流行地での調査・共同研究

Smallpox Diagnostics: Global Preparedness

Stephanie L. Lee¹, Antonio Di Caro², Anne Laure Favier³, Allen R. Grolla⁴, Sandra Lacôte⁵, Shigeru Morikawa⁶, Andreas Nitsche⁷, Hiram Olivera⁸, Pia Zimmermann⁹, Inger K. Damon¹


¹Centers for Disease Control and Prevention, Atlanta, GA, USA; ²National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy; ³Ministry of Defense, Medical Corps, Research Center CRRSA Emile Paradé, Grenoble, France; ⁴Public Health Agency of Canada, Winnipeg, Canada; ⁵Jean Mérieux BSL4/INSERM, Lyon, France; ⁶National Institute of Infectious Diseases, Tokyo, Japan; ⁷Robert Koch-Institut, Berlin, Germany; ⁸National Institute for Epidemiological Diagnosis and Reference, Mexico City, Mexico; ⁹Bundeswehr Institute of Microbiology, Munich, Germany




◇ **GHSAG Laboratory Network (GHSAGLN)** is a network of high level laboratories to co-ordinate, standardize and validate diagnostic capabilities and contribute to global health surveillance and response to disease outbreak (3). GHSAGLN also addresses challenges related to transporting diagnostic specimens and reference materials across international borders (4).

Summary of Results

- ◇ All participants correctly identified the variola strains - most detecting at the concentration level of 1fg/μl
- ◇ 3 out of 6 countries identified an orthopoxvirus in the raccoonpox sample (North American orthopoxvirus)
- ◇ One country had a false positive result as variola in one of the negative controls and another country had an indeterminate result with the same control



例) Sensitivity and specificity of IF method
using EBO-rNP expressing HeLa cells 


	IF positive	Negative
EBO-patient' s sera	14	0
Non-EBO-patient' s sera	1	51

Sensitivity; 100%
Specificity; 98%

IgG-ELISA using recombinant arenavirus-NP




Purification of arenavirus NP



Expression and purification of Lassa, Junin, and other arenavirus NP by recombinant baculoviruses

IgG-ELISA




例) Comparison of IgG-ELISA using authentic Junin Ags and rec NP



Sample	Viral Ag	rAg
Neg control	Neg	<100
#77342	Neg	<100
#77342	400	200
#77342	400	400
#77342	1600	12800
#77216	1600	400
#77216	400	3200
#78401	6400	12800
#78401	6400	51200
#51172	400	800
#23139	Neg	<100
#76482	6400	6400
#34600	1600	200
#76916	1600	6400
#34657	ND	400
#52718	ND	1600

ELISA titer




Comparison of rAg-based IgG-ELISA and Authentic IgG-ELISA (scatter diagram)

感染研のウイルス性出血熱診断法の適用例




CCHF patient in China in 2001



Laboratory test for the CCHF-patient 2001



Days from onset (Days)	1	5	9
RT-PCR (nested)	+	-	-
Ag-capture ELISA (OD ₄₀₅)	0.38	0.01	0.00
IgG-ELISA (1:100)	0.08	0.94	1.88
(OD ₄₀₅) (1:400)	0.03	0.49	0.97
IgM-capture ELISA			
(OD ₄₀₅) (1:100)	0.00	2.69	2.71
(1:400)	0.02	2.67	2.71



診断法のまとめ



感染症	発生	ウイルス	検査法						
			ELISA	IF	NT	Ag detection	PCR	LAMP	
南米出血熱	アルゼンチン出血熱	Argentine	Junin	NP	NP / GP	VSV-pseudo	NP	(RT-PCR)	
	ボリビア出血熱	Bolivia	Machupo	(NP)	NP / GP	(VSV-pseudo)	NP	(RT-PCR)	
	ベネズエラ出血熱	Venezuela	Guanarito	(NP)	NP / GP	(VSV-pseudo)	NP	(RT-PCR)	
	ブラジル出血熱	Brazil	Sabia	(NP)	NP / GP	(VSV-pseudo)	NP	(RT-PCR)	
	未定	Bolivia	Chapare	(NP)	NP / GP	(VSV-pseudo)	NP	(RT-PCR)	
ラッサ熱	西アフリカ	Lassa	NP	NP / GP	VSV-pseudo	NP	RT-PCR		
未定	Zambia	Lujo	(NP)	NP / GP	(VSV-pseudo)	NP	(RT-PCR)		
エボラ出血熱	DRC周辺	Zaire ebola	NP / GP	NP / GP	VSV-pseudo	NP	RT-PCR		
	Sudan	Sudan ebola	NP / GP	NP		NP	RT-PCR		
	Uganda	Bundibugyo ebola	(NP)	(NP)		(NP)	(RT-PCR)		
	Côte d'Ivoire	Cote d'Ivoire ebola	NP / GP	NP		NP	RT-PCR		
	Philippines	Reston ebola	NP / GP	NP / GP	VSV-pseudo	NP	RT-PCR		
マールブルグ病	Angola, Uganda, Kenya, DRC	Lake Victoria Marburg	NP	NP	VSV-pseudo	NP	RT-PCR	LAMP	
ニパウイルス感染症	Malasia, Pakistan	Nipah	NP/M/G		(VSV-pseudo)		RT-PCR		
ハンタウイルス感染症候群	北米	Sin Nombre	NP				RT-PCR		
	南米	Andes	NP			dNP-ELISA dNP-ELISA	RT-PCR		
リフトバレー熱	アフリカ、中東	Rift valley fever	NP, virus	virus	VSV-pseudo, virus	NP	(RT-PCR)		
チクングニア熱	アフリカ、アジア	Chikungunya	virus (IgM)		virus		RT-PCR		
新興ウイルス感染症	?	?	遺伝子組換えの大臣確認実験申請では対応が間に合わない				CoCoMo primer RDV		




重篤な新興ウイルス感染症

最近のウイルス性出血熱等



- 新型・新種のウイルスによるウイルス性出血熱等
 - 新種の旧世界アレナウイルスによるウイルス性出血熱(ザンビア・南ア2008 / Lujo virus)
 - 新種の新世界アレナウイルスによる南米出血熱(ボリビア2007、Chapare virus)
 - 新世界アレナウイルスの異なるcladeのウイルス間でのS-segment RNA内のNP遺伝子末端での組換えによる新型アレナウイルスの発生(カリフォルニア1999/2000 / Whitewater Arroyo virus)
 - 新型(新種)のエボラウイルスの出現(ウガンダ2007-8、Bundibugyo ebolavirus)
 - Severe fever with thrombocytopenia syndrome (SFTS) (遼寧省、山東省、江蘇省、安徽省、湖北省、河南省2008)
- 輸入感染症としてのウイルス性出血熱の発生
 - マールブルグ熱のオランダ、米国での初めての患者発生
 - ラッサ熱患者の英国での発生
 - 想定されない動物からの危険なウイルスの検出
 - 輸入齧歯類からのサル痘患者発生(米国2003、約70名)
- 動物からのウイルス検出
 - ブタのエボラウイルス感染
 - オオコウモリからヘニパウイルスが検出(アジア諸国やアフリカ)
 - サルのジステンパーウイルス感染症(中国、日本2008)

Emerging arenavirus HF in Zambia and South Africa in 2008



2008: Hemorrhagic fever due to novel Old World arenavirus, Zambia and South Africa

▲ to top

On October 2, CDC-Zambia notified CDC's Special Pathogens Branch about a cluster of 2 cases of a fatal febrile illness suspected to be a viral hemorrhagic fever, with probable person-to-person transmission. Both patients were medevaced from Zambia to South Africa and died there. During hospitalization, further transmission occurred in three other hospital workers, two of whom also subsequently died. Preliminary results indicate that the causative agent is a novel Old World arenavirus distinct from other arenaviruses such as Lassa and LCM. CDC's Special Pathogens Branch and Infectious Diseases Pathology Branch have been working closely with colleagues in CDC-Zambia, the Special Pathogens Unit, National Institute of Communicable Diseases (NICD) in South Africa, and CDC-South Africa as well as the respective National Ministries of Health to provide laboratory and epidemiologic support.


- [WHO information about the cases in Zambia and South Africa](#)
- [National Institute for Communicable Diseases, South Africa information about the cases in Zambia and South Africa](#)

OPEN ACCESS Freely available online

PLOS PATHOGENS



Genetic Detection and Characterization of Lujo Virus, a New Hemorrhagic Fever-Associated Arenavirus from Southern Africa



新種の旧世界アレンウイルスによるウイルス性出血熱の発生(ザンビア・南ア 2008 / Lujo virus)

旧世界アレンウイルスのいずれともかなり異なり、特にエンベロープ蛋白は旧世界と新世界アレンの中間に位置する。

A new arenavirus isolated from South American HF patient in Bolivia in 2008



OPEN ACCESS Freely available online

PLoS PATHOGENS

Chapare virus, a Newly Discovered Arenavirus Isolated from a Fatal Hemorrhagic Fever Case in Bolivia

Simon Delgado¹, Bobbie R. Erickson², Roberto Agudo³, Patrick A. Blair⁴, Efrain Vallejo⁵, César G. Aguilar², Juan Manuel Torres A. Camacho³, Carlos G. Quiroga³, Thomas G. Kitzel⁶, James G. Olson⁴,







Figure 1. Map of Bolivia showing location of the Chapare virus collection sites (Machupo, Chapare, and Latino) in the Beni region where hemorrhagic fever with renal failure cases occurred. The Beni Department (bordered) is adjacent to the national city, Sucre. The topographic map was taken from the 2000 USGS Topographic Data. The exact latitude and longitude coordinates are indicated in the text.

Clade A と B の南米アレナウイルスの組換えによる Whitewater Arroyo virus の出現



A (N amino acid sequence data)

B (GPC amino acid sequence data)



WWAは、GPC遺伝子は南米出血熱ウイルスと同じB cladeだが、N遺伝子はその他の非病原性A cladeと同じである。

among arenavirus nucleoprotein (N) protein and (B) complete glycoprotein gene product. Horizontal branch lengths are proportional to the scale bar; numbers adjacent to the nodes indicate bootstrap support based on an analysis of 500 pseudoreplicate data sets. PIC, Pichinde; WWA, Whitewater Arroyo; JUN, Junin; MAC, Machupo; TCR, Tacaribe; SAB, Sabiá; OLV, Oliveros; LAS, Lessa; and LCM, lymphocytic choriomeningitis virus.

WWAの様な組換えにより新興したウイルスは、日本で整備しているN蛋白を検出する抗原検出系や抗体検出系では対応できない！

新種のエボラウイルスによるアウトブレイク発生 (2007-8)



Year	Country	Virus species*	Cases	Deaths	Case fatality(%)
1976	Sudan	Sudan	284	151	53
1976	Zaire (DRC)	Zaire	318	280	88
1977	Zaire (DRC)	Zaire	1	1	100
1979	Sudan	Sudan	34	22	65
1994	Gabon	Zaire	52	31	60
1994	Cote d'Ivoir	Cote d'Ivoir	1	0	0
1995	Liberia	Cote d'Ivoir	1	0	0
1995	DRC	Zaire	315	250	79
1996	Gabon	Zaire	37	21	57
1996 - 1997	Gabon	Zaire	60	45	75
1996	South Africa	Zaire	1 **	1	100
2000 - 2001	Uganda	Sudan	425	224	53
2001 - 2002	Gabon	Zaire	65	53	82
2001 - 2002	DRC	Zaire	59	44	75
2002 - 2003	DRC	Zaire	143	128	90
2003	DRC	Zaire	35	29	83
2004	Sudan	Sudan	17	7	41
2004	Sudan	Sudan	20	5	25
2005	DRC	Zaire	12	9	75
2007	DRC	Zaire	249	183	73
2007 - 2008	Uganda	Bundibugyo	149	37	25
2008-2009	DRC	Zaire	36 ?	12 ?	33
Total			2314	1533	

Ebola-Reston was detected in October 1989 in Reston, Virginia (USA) in a colony of cynomolgus monkeys imported from the Philippines, and in November 1989 in Philadelphia, Pennsylvania, also in monkeys imported from the same supplier. Subsequent outbreaks of Reston-Ebola disease in nonhuman primates occurred in 1990 in the USA (Reston, Virginia and Alice, Texas), in 1992 in Italy (Sienna), and in 1996 in the USA (Alice, Texas). Investigations traced the source of all outbreaks caused by the Reston strain to one export facility in the Philippines (Laguna Province), but the mode of contamination of this facility was not elucidated. Although highly pathogenic for nonhuman primates, the Reston strain has not to date caused illness in humans.

A new species of ebolavirus isolated in Ebola HF in Uganda in 2007-8





FIG. 1. Geographic locations of Ebola HF outbreaks and phylogenetic relationships of representative filoviruses. (A) Map of Africa (with the sites of all known ebolavirus outbreaks denoted by colored circles for Zaire ebolavirus (yellow), Sudan ebolavirus (green), and Cote d'Ivoire ebolavirus (red)). The expanded map of Uganda shows the location of Bundibugyo and Yalu (black circles) in western Uganda, the site of the recent outbreak of Bundibugyo ebolavirus. Also shown on the Uganda map are the cities of Kampala (capital), Entebbe (international airport) and Gulu (the site of an outbreak of Sudan ebolavirus in 2000, the largest known Ebola HF outbreak on record). (B) Phylogenetic tree comparing full-length genomes of ebolavirus and marburgvirus by Bayesian analysis. Posterior probabilities greater than 0.5 and maximum likelihood bootstrap values greater than 50 are indicated at the nodes.

Bundibugyo ebolavirusは、これまでの
filovirus共通RT-PCRで検出できなかった！

Ebola virus (Reston) infection among pigs in the Philippines in 2008



World Health Organization

العربية | 中文 | English | Français | Русский | Español

Search

All WHO This site only

Home	Epidemic and Pandemic Alert and Response (EPR)
About WHO	Country activities Outbreak news Resources Media centre
Countries	WHO > Programmes and projects > Epidemic and Pandemic Alert and Response (EPR) > Diseases covered by EPR > Influenza > Global influenza surveillance TEST
Health topics	@ printable version
Publications	
Data and statistics	Ebola Reston found in domestic pigs in the Philippines
Programmes and projects	Frequently asked questions about Ebola Reston virus and human health
EPR Home	Situation update
Alert & Response Operations	On Wednesday December 10, 2008, the Philippine Department of Agriculture and the Philippine Department of Health announced that an Ebola virus of the Reston species has been identified from sick pigs in three locations in the Philippines. This is the first time globally that domestic pigs are reported to have been infected with an Ebola virus.
Diseases	
Global Outbreak Alert & Response Network	In 2008, high rates of sickness and death in pigs prompted the Philippines Veterinary Services to launch an investigation. Testing of pig samples taken in May, June and September 2008 confirmed that pigs from Nueva Ecija, Bulacan and Pangasinan provinces were co-infected with Porcine Respiratory Reproductive Syndrome (PRRS) virus and the Ebola Reston virus.
International Health Regulations	As a precaution, the affected areas are currently under full quarantine. The Philippines Department of Agriculture is reporting that there are currently no reports of unusual illness or deaths in pigs on the affected farms. In addition the Department of Agriculture also states that, nationwide, there are currently no reports of unusual illness or unexpected deaths in pigs.
Biorisk Reduction	

新型ウイルス・新興ウイルスへの迅速対応法の構築



診断法のまとめ





感染症	発生	ウイルス	検査法						
			ELISA	IF	NT	Ag detection	PCR	LAMP	
出血熱	アルゼンチン出血熱	Argentina	Junin	NP	NP/GP	VSV-pseudo	NP	(RT-PCR)	
	ボリボ出血熱	Bolivia	Machupo	(NP)	NP/GP	(VSV-pseudo)	NP	(RT-PCR)	
	ベネズエラ出血熱	Venezuela	Guanarito	(NP)	NP/GP	(VSV-pseudo)	NP	(RT-PCR)	
	ブラジル出血熱	Brazil	Sabia	(NP)	NP/GP	(VSV-pseudo)	NP	(RT-PCR)	
未定		Bahia	Chapare	(NP)	NP/GP	(VSV-pseudo)	NP	(RT-PCR)	
エボラ熱	西アフリカ	Lassa		NP	NP/GP	VSV-pseudo	NP	(RT-PCR)	
未定	Zambia	Luján						(RT-PCR)	
エボラ出血熱	DRC/周辺	Zaire ebola	NP/GP	NP/GP	VSV-pseudo	NP	RT-PCR		
	Sudan	Sudan ebola	NP/GP	NP		NP	RT-PCR		
	Guinea	Bundibugyo ebola	(NP)	(NP)		(NP)	(RT-PCR)		
	Cote d'Ivoire	Cote d'Ivoire ebola	NP/GP	NP		NP	RT-PCR		
	Philippines	Reston ebola	NP/GP	NP/GP	VSV-pseudo	NP	RT-PCR		
	Angola, Uganda, Kenya, DRC	Lake Victoria	Mandibung	NP	NP	VSV-pseudo	NP	RT-PCR, LAMP	
マールブルグ熱	Malasia, Pakistan	Nipah	NP/MG		(VSV-pseudo)		(RT-PCR)		
ハンタウイルス感染症	北米	Sin Nombre	NP				RT-PCR		
	南米	Andes	NP				RT-PCR		
リフトバレー熱	アフリカ、中東	Kilb valley fever	NP, virus	virus	VSV-pseudo	NP	(RT-PCR)		
ネタンゴニア熱	アフリカ、アジア	Chikungunya	virus (IgM)		virus		RT-PCR		
新興ウイルス感染症	?	?	遺伝子組換えの大臣確認実験申請では対応が間に合わない				CoCoMo primer	RDV	



未知のウイルス遺伝子の配列: specific primerを使えない

**非特異的な増幅産物を
ダイレクトシーケンスする必要がある**

クローニングは大臣確認必要: 承認まで時間を要する










ウイルス性出血熱が疑われる場合 の感染研の窓口

- 感染症情報センター
- ウイルス第一部

(原因不明の感染症が疑われる場合も感染研へ御連絡ください)

国連(UN)規格のカテゴリーA容器 サンプル

検体と輸送法



- ✓ 全血の場合 (PCRが陰性になるためヘパリンは不可、EDTAはOK)
- ✓ その他の検体は、疑う感染症による
- ✓ 検査の手続き
 - 行政検査手続き
 - 感染研検定係
 - 検体の輸送法
 - UN規格カテゴリーA




Viral haemorrhagic fevers: risk assessment and clinical care

Dr Barbara Bannister
Royal Free Hospital

Arenavirus family

- Old-world: Lassa, which causes sporadic and epidemic cases in West Africa; Lujo, a virus originating in Zambia, which caused an outbreak of five cases and four deaths in 2008
- New world: Junin (Argentina), Machupo (Bolivia), Guanarito (Venezuela) and Sabia (Brazil)
- Many arenaviruses non-pathogenic to humans (eg Moipea) are recognised in rodents, especially in Africa



Lassa viruses

- Four lineages: I-III Nigerian and VI, the Josiah strain from Sierra Leone, which is very similar to isolates from Liberia and Guinea
- The three Nigerian lineages show large sequence-differences in NP and GP-1 genes; up to 27% nucleic acid and 15% amino-acid divergence (*Bowen MD et al. J virol 2000: 74: 6992*)

Clinical features of Lassa fever

- Phase 1: 7 to 8 days of fever, malaise, headache, sore throat (sometimes exudative tonsillitis), muscle aches
- Phase 2: swelling of face and neck, slight fall in blood pressure, nosebleeds, microscopic haematuria, sometimes encephalopathy or nerve deafness
- Phase 3 after 10-12 days: shock, sepsis, multi-organ failure (severe haemorrhage may not occur, but indicates

Differential diagnosis of Lassa fever

- Malaria (do not neglect this treatable condition)
- Common infections, eg urinary infections, acute pharyngitis or tonsillitis, HIV seroconversion
- many viral infections, including hepatitis A, hepatitis E, yellow fever,
- Typhoid fever
- Rickettsial infections

Laboratory investigations 1

- Phase 1: moderate rise in C-reactive protein, low or normal white cell count, usually normal haemoglobin, liver function tests and coagulation tests
- Phase 2: Aspartate transaminase rises (may reach 400-2000 u/l and peaks for about three days); alanine transaminase shows much less elevation; SpO₂ may fall below 95%; platelet count falls moderately; pancreatic lipase and muscle enzymes (eg creatine kinase) may rise

Laboratory investigations 2

- Phase 3: oxygen saturation falls quickly, platelet count falls rapidly, creatinine rises with onset of renal failure, electrolyte levels may alter as major capillary leak occurs, blood albumin falls rapidly
- Patient management lab tests now focus on managing the sepsis syndrome and detecting secondary conditions such as urinary infection and ventilator-associated pneumonia